- About Us
- How We Help
- News & Media
- Get Involved
- Donate Now
Many important studies were presented last week at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Los Angeles, CA. Among them were two studies that were covered in multiple media outlets, including the New York Times (click here to read the article). The first study looked at more than 13,000 women with ovarian cancer and found that women are 30 percent less likely to die of ovarian cancer if they have guideline-recommended treatment. Yet, nearly two-thirds of those women do not receive it. Guidelines for ovarian cancer specify types of surgical procedures and chemotherapy, often the need for debulking surgery prior to chemotherapy. The study found that surgeons who were more experienced in gynecologic oncology surgery, and hospitals that treated more women with ovarian cancer, were more likely to follow the guidelines, which translated to better outcomes for their patients. The second study looked at the method of delivery of chemotherapy to patients. Intraperitoneal (IP) chemotherapy, where chemotherapy drugs are pumped directly into the abdomen, utilizes the same chemotherapy agents often administered intravenously. While IP chemotherapy is more toxic, and logistically more complicated than IV chemotherapy, there is clearly a benefit in terms of survival rate.
For you, the patient, these studies underscore the importance of making sure that you act as your own advocate by asking to be treated by a physician with ovarian cancer expertise and experience who practices according to available guidelines. For ovarian cancer information and support, please call Sharsheret at 866.474.2774 or e-mail email@example.com.
Ethan Wasserman, MD
Sharsheret Medical Advisory Board Member
© 2015 Sharsheret: Your Jewish Community Facing Breast Cancer
Sharsheret is a 501(c)(3) charitable organization ID# 13-4198529
Designed by Firefly Partners